Lanean...
Improving CAR T Cell Therapy by Optimizing Critical Quality Attributes
Whether as a cure or bridge to transplant, chimeric antigen receptor (CAR)-T cell therapies have shown dramatic outcomes for the treatment of hematologic malignancies, and particularly relapsed/refractory B cell leukemia and lymphoma. However, these therapies are not effective for all patients, and...
Gorde:
| Argitaratua izan da: | Semin Hematol |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7518470/ https://ncbi.nlm.nih.gov/pubmed/32892841 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1053/j.seminhematol.2020.07.005 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|